ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0624

Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Based on Serological Profiles: Focus on Anti-Centromere Antibody (ACA) and Anti-RNA Polymerase III (ARA) Antibodies
Abstract Number: 0625

Use of Heated Gloves for Raynaud’s Phenomenon in Systemic Sclerosis
Abstract Number: 0626

Clinical Features of Anti-hUBF Antibodies-positive Patients: A Single-center Retrospective Study
Abstract Number: 0627

Clinical Significance of Anti-Ro/SSA Antibodies in Patients with Systemic Sclerosis: A Study from the EUSTAR Database
Abstract Number: 0628

Interstitial Lung Disease in Very Early Systemic Sclerosis
Abstract Number: 0629

Negative Affect, Anxiety and Fatigue Moderate the Association Between Pain Intensity and Physical Function in People with Systemic Sclerosis
Abstract Number: 0630

Prevalence and Risk Factors for Systemic Sclerosis Digital Ischemic Complications in the Collaborative National Quality and Efficacy Registry
Abstract Number: 0631

Safety of Radiotherapy for Malignancy in Systemic Sclerosis. a Systematic Review
Abstract Number: 0632

A Longitudinal Analysis of Mouth Opening in 1101 Systemic Sclerosis Patients from the French National Cohort Study
Abstract Number: 0633

Prediction of Progressive Fibrosing Interstitial Lung Disease in Systemic Sclerosis Patients: Insight from the CRDC Cohort Study
Abstract Number: 0634

Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study
Abstract Number: 0635

Clinical Characteristics and Longitudinal Outcomes of Patients with Childhood-Onset Systemic Sclerosis at a Tertiary Center
Abstract Number: 0636

Chasing Pain: Investigating Somatosensory Profiles in Patients with Rheumatological Diseases Using Quantitative Sensory Testing
Abstract Number: 0637

Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort
Abstract Number: 0638

Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].